Literature DB >> 24378287

Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

J S Yi1, A Guidon2, S Sparks1, R Osborne1, V C Juel2, J M Massey2, D B Sanders2, K J Weinhold1, J T Guptill3.   

Abstract

Muscle specific tyrosine kinase myasthenia gravis (MuSK MG) is a form of autoimmune MG that predominantly affects women and has unique clinical features, including prominent bulbar weakness, muscle atrophy, and excellent response to therapeutic plasma exchange. Patients with MuSK MG have predominantly IgG4 autoantibodies directed against MuSK on the postsynaptic muscle membrane. Lymphocyte functionality has not been reported in this condition. The goal of this study was to characterize T cell responses in patients with MuSK MG. Intracellular production of IFN-gamma, TNF-alpha, IL-2, IL-17, and IL-21 by CD4+ and CD8+ T cells was measured by polychromatic flow cytometry in peripheral blood samples from 11 Musk MG patients and 10 healthy controls. Only one MuSK MG patient was not receiving immunosuppressive therapy. Regulatory T cells (Treg) were also included in our analysis to determine if changes in T cell function were due to altered Treg frequencies. CD8+ T cells from MuSK MG patients had higher frequencies of polyfunctional responses than controls, and CD4+ T cells had higher IL-2, TNF-alpha, and IL-17. MuSK MG patients had a higher percentage of CD4+ T cells producing combinations of IFN-gamma/IL-2/TNF-gamma, TNF-alpha/IL-2, and IFN-gamma/TNF-alpha. Interestingly, Treg numbers and CD39 expression were not different from control values. MuSK MG patients had increased frequencies of Th1 and Th17 cytokines and were primed for polyfunctional proinflammatory responses that cannot be explained by a defect in CD39 expression or Treg number.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Human; MuSK protein; Myasthenia gravis; Regulatory; T-lymphocytes

Mesh:

Substances:

Year:  2013        PMID: 24378287      PMCID: PMC4230445          DOI: 10.1016/j.jaut.2013.12.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  99 in total

1.  A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C.

Authors:  M Janer; A Cowland; J Picard; D Campbell; P Pontarotti; J Newsom-Davis; M Bunce; K Welsh; A Demaine; A G Wilson; N Willcox
Journal:  Hum Immunol       Date:  1999-09       Impact factor: 2.850

2.  Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG).

Authors:  Y M Huang; P Kivisäkk; V Ozenci; R Pirskanen; H Link
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

3.  Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants.

Authors:  Wen-Hua Xu; Ai-Mei Zhang; Ming-Shan Ren; Xu-Dong Zhang; Fang Wang; Xiu-Cai Xu; Qing Li; Jian Wang; Bang-Sheng Din; Yuan-Bo Wu; Gui-Hai Chen
Journal:  J Clin Immunol       Date:  2012-03-31       Impact factor: 8.317

4.  Clinical and experimental features of MuSK antibody positive MG in Japan.

Authors:  K Ohta; K Shigemoto; A Fujinami; N Maruyama; T Konishi; M Ohta
Journal:  Eur J Neurol       Date:  2007-09       Impact factor: 6.089

5.  In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis.

Authors:  C Aime; S Cohen-Kaminsky; S Berrih-Aknin
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

6.  [Detection of interleukin-6 in serum and cerebrospinal fluid of patients with neuroimmunological diseases].

Authors:  K Shimada; C S Koh; N Yanagisawa
Journal:  Arerugi       Date:  1993-08

Review 7.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

8.  Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells.

Authors:  Q Yi; R Ahlberg; R Pirskanen; A K Lefvert
Journal:  J Neuroimmunol       Date:  1994-03       Impact factor: 3.478

9.  Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families.

Authors:  V Guigou; D Emilie; S Berrih-Aknin; F Fumoux; M Fougereau; C Schiff
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

10.  Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis.

Authors:  Xiang Li; Bao-Guo Xiao; Jian-Ying Xi; Chuan-Zhen Lu; Jia-Hong Lu
Journal:  Clin Immunol       Date:  2007-11-28       Impact factor: 3.969

View more
  32 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  CD8+ Foxp3+ T Cells Affect Alveolar Bone Homeostasis via Modulating Tregs/Th17 During Induced Periodontitis: an Adoptive Transfer Experiment.

Authors:  Y K Han; Y Jin; Y B Miao; T Shi; X P Lin
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

Review 3.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 4.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

5.  Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.

Authors:  Yingkai Li; Jeffrey T Guptill; Melissa A Russo; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; James F Howard; Manisha Chopra; Weibin Liu; John S Yi
Journal:  Exp Neurol       Date:  2018-11-22       Impact factor: 5.330

Review 6.  Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.

Authors:  Rebecca L Hurst; Clifton L Gooch
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

Review 7.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

8.  Adaptive immune response to therapy in hmgcr autoantibody myopathy.

Authors:  John S Yi; Melissa A Russo; Kent J Weinhold; Jeffrey T Guptill
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

9.  Unique topics and issues in rheumatology and clinical immunology.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

10.  Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis.

Authors:  John S Yi; Melissa A Russo; Shruti Raja; Janice M Massey; Vern C Juel; Jay Shin; Lisa D Hobson-Webb; Karissa Gable; Jeffrey T Guptill
Journal:  Exp Neurol       Date:  2019-12-12       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.